Ulm Universita, Department of Neurology
Ulm, Baden-Wurttemberg, 89081, Germany
Location status: Recruiting
Location contact
Christine Herrmann, Dr.
CONTACT
Christine Herrmann, Dr.
PRINCIPAL_INVESTIGATOR
Johannes Dorst, Prof. Dr.
SUB_INVESTIGATOR
NCT Number: NCT06877143
Weight loss is a known negative prognostic factor in amyotrophic lateral sclerosis (ALS). Over the last years, various interventional studies targeting the energy deficit in ALS yielded promising results; however,it is still unclear which kind of nutrition or nutritional supplement is most beneficial. Moreover, there is lack of evidence regarding interventions in patients with a PEG in later disease stages.In a pilot study conducted in 2013, it was demonstrated that body weight can be stabilized in ALS by applying either a fat-rich or carbohydrate-rich high-caloric food supplement. In 2014, Wills et al. conducted a placebo-controlled randomized controlled pilot study, which indicated that a carbohydrate-rich, hypercaloric diet, consisting in 125% of estimated energy requirements as determined by indirect calorimetry, in patients fed via percutaneous endoscopic gastrostomy was safe and well tolerated. Moreover, these patients showed longer survival than patients fed with a fat-rich, hypercaloric diet or an isocaloric diet . Hypercaloric, high-carbohydrate diet also showed beneficial effects on body weight and Body Mass Index . Although these results were promising, the low number of patients (n=24) was a severe limiting factor of this study. The aim of this study is to investigate the effect of a hypercaloric PEG nutrition, consisting of 120% of estimated calorie requierements, compared to an isocaloric nutrition. Individual energy requirement is determined by performing indirect calorimetry and activity questionnaire. The investigators hypothsize, that a hypercaloric PEG nutrition slows down disease progression as measured by neurofilament light chains (NfL) in serum after 6 months compared to placebo. Power calculation relies on the results of the lipids and calories for ALS (LIPCAL-ALS) study which tested the effect of an oral high-caloric fatty nutritional supplement in ALS. The study revealed that NfL serum values declined significantly in the intervention group while remaining stable in the placebo group over the course of the study. Assuming a similar effect size, we calculated that 76 patients had to be included in the current trial.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Ulm, Baden-Wurttemberg, 89081, Germany
Location status: Recruiting
Christine Herrmann, Dr.
CONTACT
Christine Herrmann, Dr.
PRINCIPAL_INVESTIGATOR
Johannes Dorst, Prof. Dr.
SUB_INVESTIGATOR
Patients eligible for study participation will be randomized to one of two groups (hypercaloric or isocaloric diet) at baseline visit. Intervention or control diet will be administered as an add-on to standard therapy. Calory requirement will be individually determined by indirect calorimetry which measures resting energy expenditure (REE) and by collecting physical activity data. Indirect calorimetry is a non-invasive procedure which allows to calculate resting energy expenditure by measuring carbon dioxide and oxygen in the expired air using a canopy hood or a full-face mask. For both groups, a standard PEG nutrition featuring a balanced ratio of fat, carbohydrates, and protein according to human requirements will be used (e.g. Fresenius Fresubin® Energy Fibre/2250 Complete).
PEG nutrition used in this study (e.g. Fresenius Fresubin® Energy Fibre/2250 Complete) is routinely used in clinical practice for feeding of patients with ALS and PEG. It is known to be well tolerable and safe. In few cases of intolerance, this standard tube feeding may be switched to another product (e. g. HiPP Sondennahrung), but the amount of calories will not be changed.
In clinical routine, energy needs are usually estimated using the Harris-Benedict-formula, based on body weight, height, sex and age. However, this formula only provides approximate values. Therefore, in this study, indirect calorimetry is used to obtain precise values of energy needs. The German version of the International Physical Activity Questionnaire Short Last 7 Days Self-administered Format (IPAQ) is used for determining the physical activity level. The total energy requirement is calculated by adding the resting energy expenditure and the activity-related calorie requirement.
In the control group, 100% of the estimated calorie requirement is administered with the goal of covering energy needs and stabilizing body weight. The hypercaloric diet in the intervention group consists in 120% of the calorie requirement determined by indirect calorimetry. Resting energy expenditure in ALS patients is 14% higher than in a healthy control cohort. We assume that activity-related energy expenditure is increased similarly. Therefore, the hypercaloric diet consisting in 120% of calorie requirement aims to cover these additional energy needs. Similarly, a recent study in patients with PEG used 125% of calorie requirement.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients receive any PEG nutrition containing the calory requirement as determined by indirect calorimetry, physical activity score and the randomized group.
Patients receive any PEG nutrition containing the calory requirement as determined by indirect calorimetry, physical activity score and the randomized group.
Time frame: 6 months
Change of neurofilament light chain (NfL) concentration in serum after 6 months compared to baseline. The change will be measured as individual NfL slope from baseline to 6 months (change per month).
Time frame: 6 months
time to death or tracheostomy
Time frame: 6 months
Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R) score, measured as individual slope (loss of points per month)
Time frame: 6 months
Body Mass Index (BMI), weight (in kg) and height (in m) will be combined to report BMI in kg/m^2
Time frame: 6 months
Slow vital capacity (sVC)
Time frame: 6 months
Resting Energy Expenditure (REE), measured by indirect calorimetry
Time frame: 6 months
Individual Quality of Life, measured by the Euro Quality of Life (EQ-5D-5L) questionnaire
Time frame: 6 months
Appetite, measured by the Council of Appetite Questionnaire (CNAQ)
Time frame: 6 months
Eating Habits, evaluated by the Ulm Nutrition Questionnaire (UNQ; see LIPCAL study)
Time frame: 6 months
Terms and frequencies of adverse eves (AEs) and serious adverse events (SAEs)
Time frame: 6 months
Fat mass (% of total body mass), measured by bioelectrical impedance analysis (BIA)
Time frame: 6 months
total body water (% of total body mass), measured by bioelectrical impedance analysis (BIA)
Time frame: 6 months
muscle mass (% of total body mass) measured by bioelectrical impedance analysis (BIA)
Time frame: 6 months
fat free mass (% of total body mass), measured by bioelectrical impedance analysis (BIA)
Time frame: 6 months
body cell mass (% of total body mass), measured by bioelectrical impedance analysis (BIA)
Time frame: 6 months
extracellular mass (% of total body mass), measured by bioelectrical impedance analysis (BIA)
Time frame: 6 months
lean body mass (% of total body mass), measured by bioelectrical impedance analysis (BIA)
Time frame: 6 months
Beta Hydroxybutyrate serum levels
Time frame: 6 months
Acetoacetate serum levels
Time frame: 6 months
Acetone concentration in urine
Time frame: 6 months
Cholesterol serum levels
Time frame: 6 months
High-density-lipoprotein (HDL) serum levels
Time frame: 6 months
Low-density-lipoprotein (HDL) serum levels
Contact information is provided by the study sponsor or research team.
Christine Herrmann, Dr.
CONTACT
Johannes Dorst, Prof. Dr.
CONTACT
University of Ulm
Other
Acronym: PEGASUS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07257302
Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS)
Kodaira, Tokyo, Japan
View Trial DetailsNCT07023835
Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS)
La Jolla, California, United States
View Trial DetailsNCT07726563
Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS)
Taipei City, Taipei, Taiwan
View Trial DetailsNCT07142291
Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS)
Scottsdale, Arizona, United States
View Trial Details